Related Experiment Video
Updated: Aug 10, 2026
Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells
Published on: June 14, 2024
Rhabdomyosarcoma lysis by T cells expressing a human autoantibody-based chimeric receptor targeting the fetal
Stefan Gattenlöhner1, Alexander Marx, Birgit Markfort
1Institute of Pathology, University of Wuerzburg, Wuerzburg, Germany. stefan.gattenloehner@mail.uni-wuerzburg.de
Abstract:
Rhabdomyosarcomas are the most frequent malignant soft tissue tumors of childhood; however, because current multimodality treatments fail to improve the poor survival rate of children with metastatic rhabdomyosarcoma, new treatments are required. We previously identified the gamma-subunit of the fetal acetylcholine receptor (fAChR) as a specific cell surface target in rhabdomyosarcoma. Here, we engineered human T lymphocytes to express chimeric receptors composed of the antigen-binding domain of a human anti-fAChR antibody joined to the signaling domain of the human T-cell receptor zeta-chain. The interaction of fAChRzeta-transduced T cells with fAChR-positive rhabdomyosarcoma cell lines, but not with fAChR-negative control cells, induced T-cell activation characterized by strong secretion of IFN-gamma and delayed lysis of tumor cells. Importantly, we found that in six of six rhabdomyosarcoma patients, chemotherapy increased fAChR expression on residual tumor cells in vivo. Our observations suggest that these fully human chimeric fAChRzeta-transduced T cells, which should be well tolerated by the patient, have potential use in vivo both as a primary treatment for rhabdomyosarcoma and as a complementary approach to eradicate residual tumor cells after chemotherapy.
Insights
New T-cell therapy targets fetal acetylcholine receptors (fAChR) on childhood rhabdomyosarcoma. Engineered T cells show promise in treating metastatic disease and eliminating residual cancer cells post-chemotherapy.
Area of Science:
- Oncology
- Immunotherapy
- Cell Therapy
Background:
- Rhabdomyosarcoma is a common childhood soft tissue cancer with poor survival rates for metastatic cases.
- Current treatments are insufficient for metastatic rhabdomyosarcoma, necessitating novel therapeutic strategies.
- The gamma-subunit of the fetal acetylcholine receptor (fAChR) has been identified as a specific target on rhabdomyosarcoma cells.
Purpose of the Study:
- To engineer human T lymphocytes to target rhabdomyosarcoma via chimeric antigen receptors (CARs).
- To evaluate the efficacy of these engineered T cells in recognizing and eliminating fAChR-positive rhabdomyosarcoma cells.
- To assess the potential of this approach as both a primary and adjuvant therapy for rhabdomyosarcoma.
Main Methods:
- Human T lymphocytes were genetically modified to express chimeric receptors (fAChRzeta).
- These receptors combined an anti-fAChR antibody's binding domain with the T-cell receptor zeta-chain's signaling domain.
- The activity of fAChRzeta-transduced T cells was tested against fAChR-positive and negative rhabdomyosarcoma cell lines and patient samples.
Main Results:
- fAChRzeta-transduced T cells demonstrated specific activation upon encountering fAChR-positive rhabdomyosarcoma cells.
- Activated T cells secreted interferon-gamma (IFN-gamma) and induced delayed tumor cell lysis.
- In six out of six rhabdomyosarcoma patients, chemotherapy was observed to increase fAChR expression on residual tumor cells in vivo.
Conclusions:
- Engineered human chimeric fAChRzeta-transduced T cells show specific anti-tumor activity against rhabdomyosarcoma.
- This T-cell therapy has potential as a primary treatment for rhabdomyosarcoma.
- The approach may also serve as an effective complementary therapy to eradicate residual tumor cells following chemotherapy.
